Last10K.com

Arch Therapeutics, Inc. (ARTH) SEC Filing 10-Q Quarterly Report for the period ending Friday, December 31, 2021

SEC Filings

Arch Therapeutics, Inc.

CIK: 1537561 Ticker: ARTH
Document And Entity Information - shares
3 Months Ended
Dec. 31, 2021
Feb. 10, 2022
Document Information [Line Items]  
Entity Central Index Key0001537561 
Entity Registrant NameArch Therapeutics, Inc. 
Amendment Flagfalse 
Current Fiscal Year End Date--09-30 
Document Fiscal Period FocusQ1 
Document Fiscal Year Focus2022 
Document Type10-Q 
Document Quarterly Reporttrue 
Document Period End DateDec. 31, 2021 
Document Transition Reportfalse 
Entity File Number000-54986 
Entity Incorporation, State or Country CodeNV 
Entity Tax Identification Number46-0524102 
Entity Address, Address Line One235 Walnut Street, Suite 6 
Entity Address, City or TownFramingham 
Entity Address, State or ProvinceMA 
Entity Address, Postal Zip Code01702 
City Area Code617 
Local Phone Number431-2313 
Entity Current Reporting StatusYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Businesstrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Entity Common Stock, Shares Outstanding 237,169,770

View differences made from one quarter to another to evaluate Arch Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Arch Therapeutics, Inc..

Continue

Assess how Arch Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Arch Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Consolidated Balance Sheets (Current Period Unaudited)
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)
Consolidated Statements Of Cash Flows (Unaudited)
Consolidated Statements Of Changes In Stockholders' Deficit (Unaudited)
Consolidated Statements Of Operations (Unaudited)
Note 1 - Basis Of Presentation And Description Of Business
Note 1 - Basis Of Presentation And Description Of Business (Details Textual)
Note 10 - Convertible Notes
Note 10 - Convertible Notes (Details Textual)
Note 11 - Payroll Protection Program Loan
Note 11 - Payroll Protection Program Loan (Details Textual)
Note 12 - Risks And Uncertainties - Covid-19
Note 13 - Subsequent Events
Note 2 - Summary Of Significant Accounting Policies
Note 2 - Summary Of Significant Accounting Policies (Details Textual)
Note 3 - Property And Equipment
Note 3 - Property And Equipment (Details Textual)
Note 3 - Property And Equipment (Tables)
Note 3 - Property And Equipment - Schedule Of Property And Equipment (Details)
Note 4 - Inventories
Note 4 - Inventories (Details)
Note 4 - Inventories (Tables)
Note 5 - Stock-Based Compensation
Note 5 - Stock-Based Compensation (Details Textual)
Note 5 - Stock-Based Compensation (Tables)
Note 5 - Stock-Based Compensation - Restricted Stock Activity (Details)
Note 5 - Stock-Based Compensation - Stock Compensation Activity (Details)
Note 6 - Registered Direct Offerings That Created Derivative Liabilities
Note 6 - Registered Direct Offerings That Created Derivative Liabilities (Details Textual)
Note 7 - Derivative Liabilities
Note 7 - Derivative Liabilities (Details Textual)
Note 7 - Derivative Liabilities (Tables)
Note 7 - Derivative Liabilities - Derivative Liability Value Assumptions (Details)
Note 7 - Derivative Liabilities - Fair Value Of Derivative Liability (Details)
Note 8 - October 2019 Registered Direct Offering
Note 8 - October 2019 Registered Direct Offering (Details Textual)
Note 9 - 2021 Registered Direct Offering
Note 9 - 2021 Registered Direct Offering (Details Textual)
Significant Accounting Policies (Policies)

Material Contracts, Statements, Certifications & more

Arch Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ARTH
CIK: 1537561
Form Type: 10-Q Quarterly Report
Accession Number: 0001851734-22-000084
Submitted to the SEC: Fri Feb 11 2022 4:15:44 PM EST
Accepted by the SEC: Fri Feb 11 2022
Period: Friday, December 31, 2021
Industry: Surgical And Medical Instruments And Apparatus

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/arth/0001851734-22-000084.htm